Entities / Company
Monte Rosa Therapeutics.
biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 17
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Monte Rosa Therapeutics and Arvinas, Inc. are listed on Nasdaq, and MarketBeat provided analyst recommendations for both companies.Some support2 reports
-
Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.Well supported6 reports1 development inside
Gone quiet
No new reports in 90+ days-
Jefferies Financial Group reissued a 'buy' rating on Monte Rosa Therapeutics, whose stock trades on the Nasdaq exchange.Some support3 reports
-
Monte Rosa Therapeutics' stock traded on the Nasdaq exchange, and the company disclosed transactions with the SEC, including an insider sale on June 24th.Some support4 reports1 development inside
-
Monte Rosa Therapeutics filed transactions via SEC Form 4 on June 29, involving Chief Medical Officer Filip Janku.Some support1 report
-
Monte Rosa Therapeutics develops molecular glue degrader medicines.Some support1 report1 development inside
-
Monte Rosa Therapeutics published key research insights in the journal Science on July 4, 2025. John Castle served as the Chief Data Officer during this publication.Speculative1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Monte Rosa Therapeutics
Events traced to Monte Rosa Therapeutics, step by step, newest first- Monte Rosa Therapeutics partnership may face changes after Novartis staff moveMonte Rosa Therapeutics may face changes to its partnership with NovartisPossible
- Greater Boston biotech boom may raise opportunities for Monte Rosa TherapeuticsIncreased biotech investment in Greater Boston may boost Monte Rosa Therapeutics' valuation and partnerships.Possible
Around Monte Rosa Therapeutics this week
News at the entities that move Monte Rosa Therapeutics most-
Novartis StructuralBristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Moves Monte Rosa Therapeutics
-
Jefferies Financial Group TransactionalGap Inc. filed with the SEC regarding institutional investment activity, and Jefferies downgraded its stock rating and target price.Moves Monte Rosa Therapeutics
-
SEC StructuralA director of Immunome, Inc. sold company stock on July 2, 2026, disclosing the transaction to the SEC.Moves Monte Rosa Therapeutics
-
TD Cowen Mentioned togetherJefferies raised its price objective on Aflac shares, while Barclays and TD Cowen issued rating updates.Moves Monte Rosa Therapeutics
-
Raymond James Financial OperationalInstitutional investors, including Oregon Public Employees Retirement Fund, purchased and increased positions in Construction Partners shares.Moves Monte Rosa Therapeutics
-
MarketBeat Mentioned togetherMarketBeat provided analyst recommendations comparing materials companies Barrick Mining and Salzgitter.Moves Monte Rosa Therapeutics
Connections
The 10 strongest of 17, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Structural
Monte Rosa Therapeutics and Novartis maintain a formal, ongoing partnership through global and exclusive licensing agreements for drug development.
-
Filip Janku Structural
Filip Janku serves as the Chief Medical Officer of Monte Rosa Therapeutics.
-
Jefferies Financial Group Transactional
Jefferies Financial Group issued a 'buy' rating on Monte Rosa Therapeutics.
-
SEC Structural
Monte Rosa Therapeutics is subject to mandatory regulatory filing and disclosure requirements enforced by the SEC.
-
Nasdaq Structural
Monte Rosa Therapeutics is a publicly listed company whose trading and existence are governed by the Nasdaq stock exchange.
-
Raymond James Financial Operational
Raymond James Financial provides financial analysis and price targets for Monte Rosa Therapeutics.
-
TD Cowen Mentioned together
TD Cowen provided a stock rating upgrade recommendation for Monte Rosa Therapeutics.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and recommendations regarding Monte Rosa Therapeutics.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventAugust 2026
1 eventShow 1 earlier month
June 2026
5 events- Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.
- Monte Rosa Therapeutics' stock traded on the Nasdaq exchange, and the company disclosed transactions with the SEC, including an insider sale on June 24th.
- Monte Rosa Therapeutics filed transactions via SEC Form 4 on June 29, involving Chief Medical Officer Filip Janku.
- Monte Rosa Therapeutics develops molecular glue degrader medicines.
- Monte Rosa Therapeutics published key research insights in the journal Science on July 4, 2025. John Castle served as the Chief Data Officer during this publication.